Loading publications…
The last 5 uploaded publications
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. , 183, DOI: https://doi.org/10.1016/j.ejca.2023.01.016.
Article62 days agoIpilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Grant A. McArthur, Alexander M Menzies (2025). Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. , DOI: https://doi.org/10.1016/s1470-2045(24)00735-6.
Article62 days agoFDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma
Li Zhou, Milton Barros, Edward Hsiao, Zeynep Eroglu, Shahneen Sandhu, Igor Samoylenko, Serigne Lo, Matteo S Carlino, George Au‐Yeung, Maria Gonzalez, Andrew J. Spillane, Thomas E Pennington, Kerwin F Shannon, Rony Kapoor, Elizabeth M. Burton, Hussein A. Tawbi, Rodabe N. Amaria, Christian U. Blank, João Pedreira Duprat Neto, Rafaela Brito de Paula, David E Gyorki, R.P.M. Saw, Sydney Ch'ng, Robert V. Rawson, Richard A. Scolyer, Inês Pires da Silva, Alexander C J van Akkooi, Georgina V Long, Alexander M. Menzies (2025). FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. , 13(3), DOI: https://doi.org/10.1136/jitc-2025-011483.
Article62 days agoCHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
Peter K. H. Lau, S.J. Harris, Melissa Eastgate, Damien Kee, Andrew Mant, Louise M. Nott, Craig Gedye, Andrisha Jade Inderjeeth, Craig Underhill, Alison M. Weppler, Roslyn Wallace, Belinda Lee, George Au‐Yeung, Narelle Williams, Daniel Ariza Ospino, Louise Gonzales, Mark Shackleton, Serigne Lo, Grant A. McArthur, Shahneen Sandhu (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. , 41(16_suppl), DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9525.
Article62 days agoNeoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba2.
Article62 days ago